



## **Tetrahydrocurcumin**

**Catalog No: tcsc3739** 

Available Sizes			
Size: 5mg			
Size: 10mg			
Specifications			
<b>CAS No:</b> 36062-04-1			
Formula: C <sub>21</sub> H <sub>24</sub> O <sub>6</sub>			
<b>Pathway:</b> Autophagy;Metabolic Enzyme/P	rotease;Metabolic Enzyme/	Protease	
<b>Target:</b> Autophagy;Cytochrome P450;Er	ndogenous Metabolite		
Purity / Grade: >98%			
<b>Solubility:</b> DMSO: ≥ 3.8 mg/mL (10.20 mN	1)		
<b>Alternative Names:</b> HZIV 81-2			

## **Product Description**

372.41

**Observed Molecular Weight:** 

Tetrahydrocurcumin is a Curcuminoid found in turmeric (*Curcuma longa*) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit **CYP2C9** and **CYP3A4**.





IC50 & Target: CYP2C9, CYP3A4<sup>[1]</sup>

In Vitro: Tetrahydrocurcumin (THC) has a number of attractive properties not shared with Curcumin that may make it superior. Tetrahydrocurcumin inhibited lipoxygenase as low as 1  $\mu$ M. Tetrahydrocurcumin is tested for its ability to inhibit CYP2C9, CYP3A4, CYP1A2 and CYP2D6. Tetrahydrocurcumin yields dose-dependent inhibition of CYP2C9, and to a lesser extent, CYP3A4. Tetrahydrocurcumin exhibits maximum inhibition of CYP2C9 and CYP3A4 at 50 to 100  $\mu$ M. Tetrahydrocurcumin does not show a consistent dose-response inhibition of CYP1A2 or CYP2D6 over the range of concentrations tested. In some cases, the percent inhibition exceeds 100%. The effect of Tetrahydrocurcumin on cancer cell viability is measured. Sup-T1 cells, T-cell lymphoblastic lymphoma cells, are treated with Tetrahydrocurcumin to determine its ability to induce growth inhibition using an MTS assay, and the corresponding IC50 values are in the mid-to-high micromolar range<sup>[1]</sup>.

In Vivo: The serum Tetrahydrocurcumin (THC) concentration versus time curve shows that more than one absorption and distribution phase is present. Initially, a rapid absorption phase with an average Tmax of 6.8  $\mu$ g/mL at 1 h is observed, followed by a short elimination phase. This is followed by two redistributions with two smaller Tetrahydrocurcumin maxima at 6 and 24 h. Both redistribution phases has similar maxima of about 1  $\mu$ g/mL. The total amount of Tetrahydrocurcumin excrets unchanged in urine was up to 8  $\mu$ g at 24 h<sup>[1]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!